Abstract：
Organ-on-chip is an innovative technique that emerged from tissue engineering and microfluidic technologies. Organ-on-chip devices (OoCs) are anticipated to provide efficient resolutions to dealing with challenges in pharmaceutical advancement and individualized illness therapies. Organ-on-chip is an advanced method that can replicate human organs\' physiological conditions and functions on a small chip. It possesses the capacity to greatly transform the drug development process by enabling the simulation of diseases and the testing of drugs. Effective integration of this advanced technical platform with common pharmaceutical and medical contexts is still a challenge. Microfluidic technology, a micro-level technique, has become a potent tool for biomedical engineering research. As a result, it has revolutionized disciplines including physiological material interpreting, compound detection, cell-based assay, tissue engineering, biological diagnostics, and pharmaceutical identification. This article aims to offer an overview of newly developed organ-on-a-chip systems. It includes single-organ platforms, emphasizing the most researched organs, including the heart, liver, blood arteries, and lungs. Subsequently, it provides a concise overview of tumour-on-a-chip systems and emphasizes their use in the evaluation of anti-cancer medications.
摘要：
芯片上器官是一种创新技术，从组织工程和微流体技术中出现。预计芯片上器官设备（OoC）将提供有效的解决方案，以应对药物进步和个性化疾病治疗方面的挑战。芯片上器官是一种先进的方法，可以在小芯片上复制人体器官的生理条件和功能。它具有通过实现疾病模拟和药物测试来极大地改变药物开发过程的能力。这种先进的技术平台与常见的制药和医疗环境的有效整合仍然是一个挑战。微流体技术，一种微观层面的技术，已经成为生物医学工程研究的有力工具。因此,它彻底改变了包括生理材料解释在内的学科，化合物检测，基于细胞的测定，组织工程,生物诊断，和药物鉴定。本文旨在概述新开发的芯片上器官系统。它包括单器官平台，强调研究最多的器官，包括心脏,肝脏,动脉,还有肺.随后，它简要概述了芯片上肿瘤系统，并强调了它们在抗癌药物评估中的应用。
